Richter's New Drug to Take Years to Offset Russia Woes, CEO SaysBy
Richter to book milestone payment in the third quarter
Cariprazine will be game-changer for Richter, CEO Bogsch says
Gedeon Richter Nyrt. is counting on the drug developed jointly with Allergan Plc to offset declines in its Russian and Ukrainian markets, once sales of the new antipsychotic take off worldwide from 2018, Chief Executive Officer Erik Bogsch said.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.